Try Mental Wellness – Lifestyle
Author:
Xilio Therapeutics, Inc.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026